EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 4.0

Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin

Queralt Martín-Saladich, Rafael Simó, Andreea Ciudin, Julia Baguña, Clara Ramirez-Serra iD, Santiago Aguadé-Bruix, Albert Roque, Maria N Pizzi, Hug Cuéllar, Nuria Roson-Gradaille, Miguel A González Ballester, Juan M Pericàs und 1 weitere

European Journal of Clinical Investigation · 2025

DOI: 10.1111/eci.70050 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2025. Verfasst von Queralt Martín-Saladich und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute (VHIR), Nuclear Medicine, Radiology and Cardiology Departments, Vall d'Heb…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fatty Liver, Insulin, Insulin Resistance. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agència de Gestió d'Ajuts Universitaris i de Recerca, Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction‐associated steatotic liver disease (MASLD) often leads to hepatic insulin resistance (IR), yet its link to liver‐specific insulin‐mediated glucose uptake (IGLU) in type 2 diabetes (T2D) remains unclear. We aimed to explore this MASLD‐T2D relationship, addressing organ‐specific IR for personalized management and risk prevention.

Methods

This cross‐sectional study included 41 T2D participants enrolled in a clinical trial (NCT02248311) undergoing biochemical analyses, anthropometric measurements and [ 18 F]FDG‐PET/CT imaging before and after hyperinsulinemic euglycemic clamp (HEC).

Findings

Two MASLD‐T2D phenotypes were identified according to their IGLU patterns, that is, with low (HepGluc[+], n = 21) and with high (HepGluc[−], n = 20) hepatic response to insulin. HepGluc[+] participants exhibited increased systemic IR (HOMA‐IR, p = .012), inflammation (interleukin 6, p = .005); alanine and aspartate aminotransferase ALT, AST ( p = .015 and p = .007); gamma‐glutamyl transferase GGT ( p = .019) and steatosis markers (liver volume, p = .006); NAFLD liver fat score, p = .0017; hepatic steatosis index, p = .02; fatty liver index, p = .008; liver stiffness measurements (LSM) ( p = .049). No statistical differences in serum‐based liver fibrosis scores were shown. To identify MASLD‐T2D phenotypes in a friendly manner, the MASLD‐T2D score based on support vector machines was developed using AST, ALT and GGT (AUC = .83), as well as with MASLD indices including LSM and NAFLD liver fat score (AUC = .90).

Implications

Two new MASLD‐T2D phenotypes have been identified, HepGluc[+] and HepGluc[−], according to IGLU patterns, with HepGluc[+] being more deleterious due to higher systemic IR, steatosis and inflammation. Phenotypes can be identified using a new function, the MASLD‐T2D score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fatty LiverInsulinInsulin ResistanceNon-alcoholic Fatty Liver DiseaseAdultAgedFemaleHumansMaleMiddle AgedAlanine TransaminaseAspartate AminotransferasesCross-Sectional StudiesFluorodeoxyglucose F18gamma-GlutamyltransferaseGlucose Clamp TechniqueInterleukin-6LiverPhenotypePositron Emission Tomography Computed Tomography

Stichwörter der Autor:innen

MASLD[18F]FDG PET/CT imaginghyperinsulinemic euglycemic clampinsulin resistanceliver metabolism

Substanzen

Alanine TransaminaseAspartate AminotransferasesFluorodeoxyglucose F18gamma-GlutamyltransferaseInsulinInterleukin-6

Autor:innen und Institutionen

  • Medical Molecular Imaging Research Group, Vall d'Hebron Research Institute (VHIR), Nuclear Medicine, Radiology and Cardiology Departments, Vall d'Hebron University Hospital (VHUH), Autonomous University Barcelona (UAB),…
  • BCN MedTech, Information and Communication Technologies Department, Pompeu Fabra University, Barcelona, Spain.
  • Diabetes and Metabolism Research Group, VHIR, Department of Endocrinology, VHUH, UAB, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain.
  • Clinical Biochemistry Research Group, VHIR, Biochemical Core Facilities, VHUH, UAB, Barcelona, Spain.
  • Catalan Institution for Research and Advanced Studies ICREA, Barcelona, Spain.

ORCID-Profile: Clara Ramirez-Serra, José Raul Herance

Förderung

  • Agència de Gestió d'Ajuts Universitaris i de Recerca
  • Instituto de Salud Carlos III

Zitieren

APA

Martín-Saladich, Q., Simó, R., Ciudin, A., Baguña, J., Ramirez-Serra, C., Aguadé-Bruix, S., Roque, A., Pizzi, M. N., Cuéllar, H., Roson-Gradaille, N., González Ballester, M. A., Pericàs, J. M., & Herance, J. R. (2025). Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.70050

Vancouver

Martín-Saladich Q, Simó R, Ciudin A, Baguña J, Ramirez-Serra C, Aguadé-Bruix S, et al. Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin. European Journal of Clinical Investigation. 2025. doi:10.1111/eci.70050

BibTeX
@article{MartnSaladich2025,
  author = {Martín-Saladich, Queralt and Simó, Rafael and Ciudin, Andreea and Baguña, Julia and Ramirez-Serra, Clara and Aguadé-Bruix, Santiago and Roque, Albert and Pizzi, Maria N and Cuéllar, Hug and Roson-Gradaille, Nuria and González Ballester, Miguel A and Pericàs, Juan M and Herance, José Raul},
  title = {Phenotypic patterns of metabolic dysfunction‐associated steatotic liver disease in type 2 diabetes: The impact of insulin},
  journal = {European Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1111/eci.70050}
}
Kostenlos starten →